文献速递淋巴瘤造血干细胞移植与细胞治疗

CAR-T时代:复发DLBCL仅达PET+部分缓解者自体移植是否仍合适?

Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?
PubMed 文献 · Blood · 2021-01-01

该研究基于CIBMTR数据库分析2003至2013年249例移植前PET/CT+部分缓解的复发DLBCL患者,比较早期化疗免疫治疗失败(ECF)与晚期复发者的结局。结论支持对化疗敏感的DLBCL继续应用auto-HCT。

要点

  • 移植前PET/CT+部分缓解的复发DLBCL,ECF与非ECF组5年PFS均为41%。
  • 数据支持对化疗敏感的复发DLBCL继续应用auto-HCT。

核心结论

  • 对于移植前PET/CT+部分缓解的化疗敏感复发DLBCL,5年PFS为41%,与复发时间无关。
  • 数据支持在CAR-T时代继续对化疗敏感的DLBCL应用auto-HCT。

研究设计与样本

  • 基于CIBMTR数据库的回顾性队列研究,纳入2003至2013年249例移植前PET/CT+部分缓解的复发DLBCL患者。
  • 按早期化疗免疫治疗失败(ECF,原发难治或诊断后12个月内复发)与晚期复发(≥12个月)分组,ECF组182例(79%原发难治),非ECF组67例。
  • 主要终点为总生存(OS),次要终点包括无进展生存(PFS)和复发。

临床怎么用

  • 对化疗敏感且移植前仅达PET/CT+部分缓解的复发DLBCL,可考虑auto-HCT巩固。
  • ECF状态与死亡风险升高相关,但PFS与复发无差异,不应仅据此排除auto-HCT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For relapsed chemosensitive diffuse large B-cell lymphoma (DLBCL), consolidation with autologous hematopoietic cell transplantation (auto-HCT) is a standard option. With the approval of anti-CD19 chimeric antigen receptor T cells in 2017, the Center for International Blood and Marrow Transplant Research (CIBMTR) reported a 45% decrease in the number of auto-HCTs for DLBCL in the United States. Using the CIBMTR database, we identified 249 relapsed DLBCL patients undergoing auto-HCT from 2003 to 2013 with a positive positron emission tomography/computed tomography (PET/CT)+ partial response prior to transplant were identified. The study cohort was divided into 2 groups: early chemoimmunotherapy failure (ECF), defined as patients with primary refractory disease (PRefD) or relapse within 12 months of diagnosis and late chemoimmunotherapy failure, defined as patients relapsing after ≥12 months. Primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS) and relapse. A total of 182 patients had ECF, whereas 67 did not. Among ECF cohort, 79% had PRefD. The adjusted 5-year probabilities for PFS and OS (ECF vs no ECF) were not different: 41% vs 41% (P = .93) and 51% vs 63% (P = .09), respectively. On multivariate analysis, ECF patients had an increased risk for death (hazard ratio, 1.61; 95% confidence interval, 1.05-2.46; P = .03) but not for PFS or relapse. In conclusion, for relapsed chemosensitive DLBCL patients with residual PET/CT+ disease prior to auto-HCT, the adjusted 5-year PFS (41%) was comparable, irrespective of time to relapse. These data support ongoing application of auto-HCT in chemosensitive DLBCL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Shah NN, Ahn KW, Litovich C, et al. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood. 2021. PMID: 33120429. doi:10.1182/blood.2020007939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。